Advertisement

Chinese Journal of Cancer Research

, Volume 15, Issue 2, pp 79–85 | Cite as

Inducement of antitumor-immunity by DC activated by Hsp70-H22 tumor antigen peptide

  • Feng Zuo-hua 
  • Huang Bo 
  • Zhang Gui-mei 
  • Li Dong 
  • Wang Hong-tao 
Article
  • 23 Downloads

Abstract

Objective: To investigate the feasibility of decreasing the dosage of tumor antigen peptides by dendritic cell (DC)-presenting and the characteristics of modification of DC by heat shock protein (Hsp70) and antigen peptides. Methods: Peptides were bound to Hsp70 and used to modify DCin vitro. The metabolism of the modified DC and the cytokines secreted by the modified DC were determined. The activation of lymphocytes by the modified DC and Hsp70-H22 peptides was tested. The cytotoxicity of the activated lymphocytes to H22 tumor cells was analyzed. The inhibitory effect of tumor in mice by the injection of DC and Hsp70-H22 peptides was tested. Results: 0.15 µ g of H22 peptides bound with Hsp70 could make 2 ×105 DC mature. 4×103 matured DC could activate 2×106 lymphocytes. The same amount of lymphocytes could be activated to produce similar cytotoxicity to tumor cells by either DC modified by 0.003µg of peptides bound with Hsp70 or by direct stimulation with 0.15 µg of peptides bound with Hsp70. The dosage of peptides could be reduced by about 50 folds if the modified DC was used for injection instead of Hsp70-peptides. Peptides from normal hepatocytes, bound with Hsp70, could not make DC mature, nor activate lymphocytes through DC. Conclusion: The dosage of Hsp70-H22 peptides can be reduced significantly by DC-presenting to activate lymphocytes. Peptides from normal cells could not activate lymphocytes by either Hsp70-presenting or DC-presenting and they have little chance to induce autoimmunity.

Key words

Hsp70 H22 peptide Dosage DC-presenting Anti-tumor immunity 

CLC number

R73-36+2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Huang Bo, Feng Zuohua, Zhang Guimei, et al. Investigation on the effect of peptides mixture from tumor cells inducing anti-tumor specific immune response[J]. Science in China (Series C) 2002; 32:165–71.Google Scholar
  2. [2]
    Basu S, Binder RJ, Ramelingam T, et al. CD91 ia a common receptor for heat shock proteins gp96, hsp70, and calreticulin[J]. Immunity 2001; 14: 303–13.PubMedCrossRefGoogle Scholar
  3. [3]
    Somersan S, Larsson M, Fonteneau JF, et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells[J]. J Immunol 2001; 167: 4844–52.PubMedGoogle Scholar
  4. [4]
    Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to cd34+ progenitor derived dendritic cell vaccine[J]. Cancer Res 2001, 61: 6451–8.PubMedGoogle Scholar
  5. [5]
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity [J]. Nature 1998; 392:245–52.PubMedCrossRefGoogle Scholar
  6. [6]
    Imai N, Harashima N, Ito M, et al. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases[J]. Int J Cancer 2001; 94:237–42.PubMedCrossRefGoogle Scholar
  7. [7]
    Murayama K, Kobayashi T, Imaizumi T, et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides[J]. J Immunother 2000; 23:511–8.PubMedCrossRefGoogle Scholar
  8. [8]
    Disis ML, Grabstein KH, Sleath PR, et al. Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine[J]. Clin Cancer Res 1999; 5:1289–97.PubMedGoogle Scholar
  9. [9]
    Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3[J]. Proc Natl Acad Sci USA 2001; 98:10290–95PubMedCrossRefGoogle Scholar
  10. [10]
    Huang Bo, Feng Zuo-hua, Zhang Gui-mei, et al. The therapeutic effect of eukaryotic expressing vector pCH510 of recombinant polypeptide of FN linking chemotherapy on tumor-bearing mice(in Chinese)[J]. Chin J Cancer Biother 2001; 8:168–72.Google Scholar
  11. [11]
    Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derivedin vitro in patients with metastatic cancer[J]. Cancer 2000; 89:2646–54.PubMedCrossRefGoogle Scholar
  12. [12]
    Srivastava PK, Menoret A, Basu B, et al. Heat shock proteins come of age:primitive functions acquire new roles in an adaptive world[J]. Immunity 1998; 8:657–65.PubMedCrossRefGoogle Scholar
  13. [13]
    Arnold-Schild D, Hanau D, Spehner D, et al. Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells[J]. J Immunol 1999; 162:3757–60.PubMedGoogle Scholar
  14. [14]
    Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex classI antigen presentation via two distinct processing pathways[J]. J Exp Med 2000; 191:1957–64.PubMedCrossRefGoogle Scholar
  15. [15]
    Shimizu K, Thomas EK, Giedlin M, et al. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein [J]. Cancer Res 2001; 61:2618–24.PubMedGoogle Scholar
  16. [16]
    Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells [J]. Blood 2000; 96:3102–8.PubMedGoogle Scholar
  17. [17]
    Tamura Y, Pehg P, Kang L, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations [J]. Science 1997; 278:117–20.PubMedCrossRefGoogle Scholar
  18. [18]
    Huang Bo, Feng Zuo-hua, Zhang Gui-mei, et al. Experimental study on the therapy of murine tumor by mixed antigen peptides from H22 hepatocarcinoma cells presented by rhHsp70(in Chinese)[J]. Chin J Microbiol Immunol 2002; 22:160–3.Google Scholar

Copyright information

© Chinese Journal of Cancer Research 2003

Authors and Affiliations

  • Feng Zuo-hua 
    • 1
  • Huang Bo 
    • 1
  • Zhang Gui-mei 
    • 1
  • Li Dong 
    • 1
  • Wang Hong-tao 
    • 1
  1. 1.Department of Biochemistry and Molecular Biology, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan

Personalised recommendations